Lab Med Qual Assur.  2024 Sep;46(3):115-129. 10.15263/jlmqa.2024.46.3.115.

Report of the Korean Association of External Quality Assessment Service on Next-Generation Sequencing-Based Liquid Biopsy (2020–2023)

• Ryu J
• Yu J
• Hong J
• Kim S
• Lee W
• Chun S

• KMID: 2559912
• DOI: http://doi.org/10.15263/jlmqa.2024.46.3.115

Abstract

Next-generation sequencing (NGS)-based liquid biopsy using peripheral blood offers a minimally invasive approach to detect tumor-derived circulating tumor DNA (ctDNA). Given the low abundance of ctDNA, accurate analysis is crucial, necessitating external quality assessments. Since 2020, the Korean Association of External Quality Assessment Service has conducted proficiency testing for NGS-based liquid biopsy. This study reviews the proficiency testing results from 2020 to 2023. The program was conducted biannually. Specimens were created by spiking fragmented DNA into fresh frozen plasma to simulate actual clinical samples. The number of target genes reported increased from 5 in 2020 to 17 in 2023. Results were assessed based on concordance with those obtained from targeted NGS panel testing performed before shipping the manufactured specimens. Participating laboratories used various NGS instruments and reagents. The read depth for each genetic variant varied across laboratories, while the reported read percentage of detected variants was generally consistent. Most laboratories accurately reported variants; however, some discrepancies related to variant position descriptions or incorrect reference sequence transcripts were noted. This study evaluates the performance of Korean clinical laboratories in NGS-based liquid biopsy. Continued vigilance in result reporting is necessary, and ongoing external quality assessments can enhance the reliability of NGS-based liquid biopsy testing.

Keyword

Liquid biopsy; Next-generation sequencing; Circulating tumor DNA; Laboratory proficiency testing